CN202078423U - Artificial crystal for slow-releasing medicines - Google Patents
Artificial crystal for slow-releasing medicines Download PDFInfo
- Publication number
- CN202078423U CN202078423U CN2011201650827U CN201120165082U CN202078423U CN 202078423 U CN202078423 U CN 202078423U CN 2011201650827 U CN2011201650827 U CN 2011201650827U CN 201120165082 U CN201120165082 U CN 201120165082U CN 202078423 U CN202078423 U CN 202078423U
- Authority
- CN
- China
- Prior art keywords
- slow
- loop
- artificial intraocular
- intraocular lenses
- hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 62
- 239000013078 crystal Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 17
- 238000000576 coating method Methods 0.000 claims abstract description 15
- 229920000642 polymer Polymers 0.000 claims abstract description 11
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 11
- 239000011248 coating agent Substances 0.000 claims description 11
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000011247 coating layer Substances 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 5
- 230000002980 postoperative effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 206010036346 Posterior capsule opacification Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- -1 pla-pcl Polymers 0.000 description 2
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 150000001349 alkyl fluorides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005995 polystyrene-polyisobutylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
The utility model relates to an artificial crystal for slow-releasing medicines, which is an artificial crystal with an improved structure. The artificial crystal comprises an artificial crystal lens which has two convex surfaces and connecting loops which extend from the ends of the artificial crystal lens; holes are formed on the connecting loops; slow-releasing medicines are filled in the holes; and anti-inflammatory polymer coatings are arranged on the surfaces of the connecting loops. In the artificial crystal for slow-releasing medicines with such a structure, the slow-releasing medicines are filled in the holes of the connecting loops, the anti-inflammatory polymer coatings are attached to the connecting loops, the releasing time of medicines is 30-150 days, and the releasing concentration and releasing time of medicines can be precisely controlled by controlling the thickness of medicine coatings and adjusting medicine content in the medicine coatings, thereby greatly prolonging the releasing time of medicines, enabling the releasing concentration and releasing time of medicines to be safer and controllable and greatly expanding the clinical application scope.
Description
Technical field
This utility model is the improvement to artificial intraocular lenses's structure, relates to a kind of artificial intraocular lenses of medicine-carried specifically.
Background technology
Along with the improvement of artificial intraocular lenses's configured and material, the maturation of cataract ultrasonic emulsification technology, more and more safe to cataractous operative treatment, the untoward reaction of postoperative is also fewer and feweri, but the inflammatory reaction of postoperative still can't be avoided.Post-operation inflammatory reaction pair posterior capsule opacification, corneal endothelium recovers, and complication such as secondary glaucoma have tangible influence.General normal use hormones of postoperative antiinflammatory and non-hormone anti-inflammatory agent carry out 2 to 3 months continuity point medicament for the eyes treatment clinically; need put drops in one's eyes in one day 3 to 6 times; caused a lot of inconvenience for the life of postoperative patient; and, increased the possibility that after cataract takes place because of the improper also regular meeting of postoperative point medicine causes infection.Owing to the existence of cornea barrier, the diluting effect of tear and the reasons such as drainage of lacrimal passage, the effect of conventional medicament for the eyes are often not good simultaneously.And at present, focus mostly in the improvement of the design of artificial intraocular lenses's configuration and material about artificial intraocular lenses's research, for artificial intraocular lenses itself carry medicine with strengthen drug effect, reduce the patient inconvenience, slow down the concern of patient suffering aspect and few.In the existing technology, relevant artificial intraocular lenses carries the medicine carrying mode of anti-inflammatory agent and punches medicine carrying in the hole on the loop for connecting the artificial intraocular lenses.The problem that this medicine carrying mode exists is to limit because of the volume that is subjected to the medicine carrying hole, drug loading is limited in the hole, the drug level adjustable range is little, be difficult to realize adopting different doses to treat at the different state of an illness, and the patient for needs prolong administration time limits the medicament slow release time because of drug loading and does not also often satisfy clinical needs.
Summary of the invention
The purpose of this utility model is exactly in order to overcome the above problems, provide a kind of can accurately control medicine carrying dosage, drug release concentration and medicament slow release time at the wider new sustained release type medicine artificial intraocular lenses of the state of an illness.
The purpose of this utility model is achieved through the following technical solutions: the slow-release medicine artificial intraocular lenses, comprise that the two sides is convexity artificial intraocular lenses eyeglass and the extended loop that is connected of crystal eyeglass end, it is characterized in that: on the connection loop, be provided with the hole, fill medicinal slow release agent in the hole, be provided with the anti-inflammatory agent polymer coating on connection loop surface.
Described connection loop is that the C type that is connected with crystal eyeglass both ends connects loop.
Described connection loop is to be connected the retractility connection loop of closo in the form of a ring with crystal eyeglass both ends.
Described C type connects end, loop end and is provided with expanding section, and the connection loop width of expanding section is 0.20 ~ 0.65mm, is provided with the hollow hole that the vertical section is taper at the expanding section place.
Described C type connects loop end segments surface and is provided with circle or ellipse hole.
Described C type connects loop and is provided with circular equal diameter kick, is provided with through hole in kick, fills medicine in the through hole.
Described retractility connects the circular outstanding end of loop outward flange and is provided with through hole.
Described coating layer thickness is 2 ~ 30 microns.
The beneficial effects of the utility model: this utility model adopts said structure, to compare advantage as follows with non-medicine type artificial intraocular lenses: 1. can simplify patient's diagnosis and treatment process, improve the operation quality, deducted special care every day of postoperative eyes, save the inconvenience that a lot of common treatment methods are brought, simultaneously also avoided having reduced the generation of after cataract because of the improper infection that eyes are caused of a medicine.2. because of the artificial intraocular lenses implants in the capsule bag of back room, avoided existence, the high amount of drug waste that the diluting effect of tear and the drainage of lacrimal passage cause, the use amount that can save medicine greatly owing to the cornea barrier.3. adopt slow releasing agent to carry out antiinflammatory, the drug releasing rate stable and controllable makes that ophthalmic anterior chamber drug level is continual and steady, has avoided because the possibility of the reaction that is inflamed when medicine effective concentration is on the low side in the anterior chamber.Compare with similar spacetabs type medicine carrying artificial intraocular lenses: owing in the hole that connects loop, fill medicinal slow release agent with antiinflammatory action, and on whole connection loop, adhere to the anti-inflammatory agent polymer coating, the medicament slow release time is 30 to 150 days, can reach accurate control drug release concentration and the effect of medicament slow release time by the thickness of controlling the medicine spraying and the mode of adjusting medicament contg in the coating, the medicine slow-release time is greatly prolonged, safety is controlled more to make medicine release concentration and medicament slow release time, has expanded clinical application range greatly.
Description of drawings
Fig. 1 is the structural representation of embodiment 1.
Fig. 2 is the structural representation of embodiment 2.
Fig. 3 is the structural representation of embodiment 3.
Fig. 4 is the structural representation of embodiment 4.
The specific embodiment
Embodiment 1: as shown in Figure 1, the slow-release medicine artificial intraocular lenses, comprise that the two sides is that convexity artificial intraocular lenses eyeglass 1 is connected loop 2,3 with the extended C type of crystal eyeglass 1 end, the terminal head place that connects loop 2,3 in the C type is provided with expanding section A, B respectively, the connection loop width of expanding section A, B is 0.20 ~ 0.65mm, be provided with the hollow hole that the vertical section is taper respectively at expanding section A, B place, in hollow hole, fill medicinal slow release agent 4,5, the surface that connects loop 2,3 in the C type sprays anti-inflammatory agent polymer coating 6,7 respectively, and coating 6,7 thickness are 2 ~ 30 microns.
Embodiment 2: as shown in Figure 2, the slow-release medicine artificial intraocular lenses, comprise that the two sides is that convexity artificial intraocular lenses eyeglass 1 is connected loop 2,3 with the extended C type of crystal eyeglass 1 end, the end segments surface that connects loop 2,3 in the C type is provided with circle or ellipse hole, in through hole, fill medicinal slow release agent 4,5, connect loop 2,3 surfaces in the C type and spray anti-inflammatory agent polymer coating 6,7 respectively, coating layer thickness 6,7 is 2 ~ 30 microns.
Embodiment 3: as shown in Figure 3, the slow-release medicine artificial intraocular lenses, comprise that the two sides is that convexity artificial intraocular lenses eyeglass 1 is connected loop 2,3 with the extended C type of crystal eyeglass 1 end, on C type connection loop 2,3, be respectively equipped with circular equal diameter kick 8,9, in kick 8,9, be respectively equipped with through hole, fill medicinal slow release agent 4,5 in through hole, connect loop 2,3 surfaces in the C type and spray anti-inflammatory agent polymer coating 6,7 respectively, coating 6,7 thickness are 2 ~ 30 microns.
Embodiment 4: as shown in Figure 4, the slow-release medicine artificial intraocular lenses, comprise that the two sides is a convexity artificial intraocular lenses eyeglass 1, the retractility that is connected closo in the form of a ring with crystal eyeglass 1 both ends connects loop 10,11, the circular jag of two of the outward flanges portion that connects loop 10,11 in retractility is provided with through hole respectively, fills medicinal slow release agent 12,13,14,15 in through hole.Fill medicine in through hole after, spray anti-inflammatory agent polymer coating 6,7 respectively on connection loop 10,11 surfaces, coating 6,7 thickness are 2 ~ 30 microns.
Wherein reaching the used slow-release medicine in connection loop surface in the foregoing description connection loop hole is made up of anti-inflammatory drug and pharmaceutical carrier-degradable polymer.Anti-inflammatory drug can be glucocorticoid or NSAID (non-steroidal anti-inflammatory drug), but also The combined is used; Polymer is formed and be can be the left-handed lactobionic acid of poly, phosphocholine, polylactic acid glycolide copolymer, pla-pcl, polyhydroxybutyrate valerate, politef, poly-alkyl fluoride, poly-ly fluoridize alkoxyl phosphoric acid nitrence polymer, fluoridizes polymethyl methacrylate, polystyrene-polyisobutylene, polyacrylate, polyurethane, polyvinyl acetate, Vinalac 5920 etc.Concrete application method can be undertaken by clinical needs.
Claims (8)
1. the slow-release medicine artificial intraocular lenses comprises that the two sides is convexity artificial intraocular lenses eyeglass and the extended loop that is connected of crystal eyeglass end, is characterized in that: be provided with the hole on the connection loop, fill medicinal slow release agent in the hole, be provided with the anti-inflammatory agent polymer coating on connection loop surface.
2. slow-release medicine artificial intraocular lenses according to claim 1 is characterized in that: described connection loop is that the C type that is connected with crystal eyeglass both ends connects loop.
3. slow-release medicine artificial intraocular lenses according to claim 1 is characterized in that: described connection loop is to be connected the retractility connection loop of closo in the form of a ring with crystal eyeglass both ends.
4. slow-release medicine artificial intraocular lenses according to claim 2 is characterized in that: described C type connects end, loop end and is provided with expanding section, and the connection loop width of expanding section is 0.20 ~ 0.65mm, is provided with the hollow hole that the vertical section is taper at the expanding section place.
5. slow-release medicine artificial intraocular lenses according to claim 2 is characterized in that: described C type connects loop end segments surface and is provided with circle or ellipse hole.
6. slow-release medicine artificial intraocular lenses according to claim 2 is characterized in that: described C type connects loop and is provided with circular equal diameter kick, is provided with through hole in kick, fills medicine in the through hole.
7. slow-release medicine artificial intraocular lenses according to claim 3 is characterized in that: described retractility connects the circular outstanding end of loop outward flange and is provided with through hole.
8. according to claim 1 or 2 or 3 described slow-release medicine artificial intraocular lensess, it is characterized in that: described coating layer thickness is 2 ~ 30 microns.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011201650827U CN202078423U (en) | 2011-05-23 | 2011-05-23 | Artificial crystal for slow-releasing medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011201650827U CN202078423U (en) | 2011-05-23 | 2011-05-23 | Artificial crystal for slow-releasing medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202078423U true CN202078423U (en) | 2011-12-21 |
Family
ID=45339082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011201650827U Expired - Lifetime CN202078423U (en) | 2011-05-23 | 2011-05-23 | Artificial crystal for slow-releasing medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202078423U (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352289A (en) * | 2014-10-27 | 2015-02-18 | 浙江大学 | Intraocular lens loaded with drug slow-releasing thin layers on loop surfaces |
| CN106901871A (en) * | 2015-12-23 | 2017-06-30 | 爱博诺德（北京）医疗科技有限公司 | Intraocular lens with one or more extentions |
| CN112402098A (en) * | 2020-11-19 | 2021-02-26 | 浙江大学 | Drug-eluting intraocular lens with slow release function and preparation method thereof |
-
2011
- 2011-05-23 CN CN2011201650827U patent/CN202078423U/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104352289A (en) * | 2014-10-27 | 2015-02-18 | 浙江大学 | Intraocular lens loaded with drug slow-releasing thin layers on loop surfaces |
| CN106901871A (en) * | 2015-12-23 | 2017-06-30 | 爱博诺德（北京）医疗科技有限公司 | Intraocular lens with one or more extentions |
| CN112402098A (en) * | 2020-11-19 | 2021-02-26 | 浙江大学 | Drug-eluting intraocular lens with slow release function and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11712370B2 (en) | Lacrimal implants and related methods | |
| CN102824238B (en) | Schlemm tube expansion bracket and combined body thereof | |
| AU2014350095B2 (en) | Eye device | |
| US20110184358A1 (en) | Pulsatile peri-corneal drug delivery device | |
| TW201006453A (en) | Lacrimal implant body including comforting agent | |
| US20100226962A1 (en) | Peri-corneal drug delivery device | |
| CN203059976U (en) | Artificial lens | |
| CN202078423U (en) | Artificial crystal for slow-releasing medicines | |
| SG174972A1 (en) | Punctal plugs | |
| A Peptu et al. | Modern drug delivery systems for targeting the posterior segment of the eye | |
| CN212213944U (en) | Hollow-out type artificial lens medicine carrying system | |
| US9259352B2 (en) | Punctal plugs | |
| US9259351B2 (en) | Punctal plugs | |
| CN202235772U (en) | Artificial lens | |
| CN103169548A (en) | Drug-carrying type artificial lens capable of being opened by laser | |
| US10172740B2 (en) | Lacrimal stent | |
| CN117357332A (en) | Tension ring for preventing post-failure | |
| Koban | Gentamicin overdose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200225 Address after: 110163 No. 66, Surabaya street, Dongling District, Liaoning, Shenyang Patentee after: Shenyang hundred Austrian medical equipment Co., Ltd. Address before: 110163 No. 66, Surabaya street, Dongling District, Liaoning, Shenyang Patentee before: He Wei |
|
| TR01 | Transfer of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20111221 |
|
| CX01 | Expiry of patent term |